Freya Biosciences
Clinical-stage biotechnology company developing live biotherapeutics to restore vaginal microbiome health, with lead candidate FYB202 for bacterial vaginosis and related conditions.
Notes
Freya Biosciences is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics for women's health. The company is developing live biotherapeutic products (LBPs) to restore healthy vaginal microbiome composition.
The company's lead candidate FYB202 is a live biotherapeutic designed to treat bacterial vaginosis (BV), a common vaginal condition affecting millions of women that is associated with increased risks of sexually transmitted infections, pregnancy complications, and recurring infections. Current antibiotic treatments have high recurrence rates, creating a need for microbiome-based approaches.
Freya's technology platform focuses on Lactobacillus strains that colonize the vaginal mucosa and create an environment hostile to pathogenic bacteria.
Team
- Leadership team includes experienced executives from microbiome and women's health companies
- Company maintains relatively low public profile
Additional Research Findings
- Founded in 2019, based in South San Francisco
- Portfolio company of CE-Ventures and other investors
- Lead candidate FYB202 for bacterial vaginosis
- Focus on live biotherapeutic products (LBPs)
- Targeting restoration of healthy vaginal Lactobacillus populations
- Addresses condition affecting ~30% of reproductive-age women
- Current BV treatments have ~50% recurrence rate
- Clinical-stage company with ongoing development programs
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| CE-Ventures (Crescent Enterprises) | Sharjah, UAE | generalist | seedseries-a+3 | 4 |
| Corundum Systems Biology | Tokyo, Japan | biotech-focused | seedseries-a+1 | 9 |
| OMX Ventures | San Francisco, California, USA | biotech-focused | seedseries-a | 23 |